Paul E. Goss, MD, PhD
Massachusetts General Hospital
10
1
9
N/A
0
9
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+12 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (10)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
James N. Ingle, MD
Mayo Clinic
Shared therapeutic areas:
Worked with same sponsors:
Michael B Gill
Power Life Sciences Inc.
Shared therapeutic areas:
Dawn Hershman, MD
Herbert Irving Comprehensive Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Lizhi Niu, PhD
Fuda Cancer Hospital
Shared therapeutic areas:
Dong-Xin Wang, MD, PhD
Peking University First Hospital
Shared therapeutic areas:
Ali MA Ismail, lecturer
Cairo University
Shared therapeutic areas:
Steven A Rosenberg, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Worked with same sponsors:
John D. Hainsworth, MD
SCRI Development Innovations, LLC
Shared therapeutic areas:
Chadwick Prodromos, MD
The Foundation for Orthopaedics and Regenerative Medicine
Shared therapeutic areas:
Aminah Jatoi, MD
Mayo Clinic
Shared therapeutic areas:
Worked with same sponsors:
Publications (0)
No publications found for this investigator.
Clinical Trials (10)
Showing 10 of 10 trials
Bone Mineral Density in Postmenopausal Women at Increased Risk of Breast Cancer And Who Are Receiving Exemestane on MAP3
Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer Who Are Receiving Treatment on Clinical Trial
Quality of Life in Postmenopausal Women Who Are Receiving Either Exemestane or Anastrozole With or Without Celecoxib for Stage I, Stage II, or Stage IIIA Primary Breast Cancer
Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer
Letrozole in Breast Cancer Who Have Received 5 Years of Aromatase Inhibitor Therapy
Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast Cancer
Exemestane in Reducing Breast Density in Postmenopausal Women at Risk for Breast Cancer
Letrozole in Preventing Breast Cancer in Postmenopausal Women Who Are at Increased Risk for Breast Cancer Due to High Breast Density
Letrozole After Tamoxifen in Treating Women With Breast Cancer
Biomarkers in Predicting Response to Tamoxifen and Letrozole in Postmenopausal Women With Primary Breast Cancer Treated on Clinical Trial CAN-NCIC-MA17
All 10 trials loaded